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Abstract
Background: Enteric fever is an important public health problem in Nepal. Due to emergence of multidrug
resistant strains of Salmonella spp. the conventional first-line drugs, ampicillin, chloramphenicol, and cotrimoxazole
have not been used as empiric therapy for treatment of enteric fever for last two decades and there have been
increased uses of fluoroquinolones as the drugs of choice. The aim of this study was to evaluate and analyze the
antimicrobial susceptibility patterns of Salmonella spp.
Methods: A total of 620 blood samples collected from the patients suspected of suffering from enteric fever were
cultured using standard microbiological techniques. Antibiotic susceptibility testing of the Salmonella spp., was
performed by Kirby Bauer disc diffusion technique following Clinical and Laboratory Standard Institute (CLSI)
guidelines. Minimum inhibitory concentrations of ciprofloxacin, ofloxacin and nalidixic acid were determined by
agar dilution method.
Results: Of the total 83 Salmonella spp., 48 (57.83 %) were S. Typhi and 35 (42.26 %) were S. Paratyphi A. Among 83
Salmonella isolates, 98.8 % of the Salmonella spp. were susceptible to chloramphenicol and co-trimoxazole and
about 97.6 % of the isolates were susceptible to ampicillin. Similarly, 69 (83.13 %) isolates were resistant to nalidixic
acid. Only 16.9 % of the isolates were susceptible to ciprofloxacin. One S. Typhi isolate was multidrug resistant.
Conclusion: The present study revealed the decreased susceptibility of the S. Typhi and S. Paratyphi A to
fluoroquinolones, proving them to be inappropriate for empirical therapy for the treatment of enteric fever in
our setting. Further the higher susceptibility of the isolates to first line drugs, ampicillin, chloramphenicol, and
cotrimoxazole suggests the possibility of using these drugs for empirical therapy.
Keywords: Enteric fever, Salmonella spp., First line antibiotics, Fluoroquinolones, Antibiotic resistance, Nepal
Background
Enteric fever is an infection caused by Salmonella
enterica serotype Typhi and Paratyphi [1]. It has been
estimated that there are worldwide, approximately 22
millions typhoid cases and 200,000 deaths per year [2].
Salmonella enterica serovar Paratyphi A causes add-
itional 5·4 millions illnesses [2]. Enteric fever, is a
serious public health problem in Nepal and is attributed
to fecal contamination of foods and drinking water [3].
Since 1989, multidrug resistant strains of Salmonella,
those are no longer susceptible to the first line antibiotics
have emerged [4]. Multidrug resistant Salmonella enterica
strains (resistant to chloramphenicol, ampicillin, cotri-
moxazole) are common in Asia [5]. During the past two
decades, more than 80 % of the known multidrug resistant
strains of Salmonella have been reported from Pakistan,
Iran, Nepal, Bangladesh and India [6, 7]. And the fluoro-
quinolones have been suggested as the drugs of choice for
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the treatment of the enteric fever caused by species of Sal-
monella resistant to first line antibiotics [8].
Over the last decade there have been several enteric
fever epidemics in Nepal [9, 10] with changing antibiotic
resistance patterns [11]. The multidrug resistant S. Typhi
in Nepal was first reported in 1991 [12]. Subsequently,
with the introduction of fluoroquinolones for the treat-
ment of enteric fever, nalidixic acid-resistant strains
associated with reduced susceptibility to fluoroquino-
lones have been increasingly reported from Nepal [10].
And the use of third generation cephalosporins and azi-
thromycin as treatment options for enteric fever has in-
creased [13]. There have been reports of occasional
isolation of the highly fluoroquinolone resistant and
third generation cephalosporin resistant strains of S.
Typhi and S. Paratyphi A from Nepal [14, 15]. And re-
cently the re-emergence of the conventional first-line
drugs susceptible strains of Salmonella spp. in Nepal has
been reported (Susceptibility of Salmonella Typhi to
chloramphenicol and cotrimoxazole was 100 % and that
to ampicillin was 98.2 %. Similarly, 100 % of S. Paratyphi
A strains were sensitive to cotrimoxazole and ampicillin
with 96.7 % of the isolates being sensitive to chloram-
phenicol) [13]. In the present situation, when the
treatment options for enteric fever are decreasing, the
re-emergence of strains of the Salmonella susceptible
to ampicillin, chloramphenicol, and cotrimoxazole
should be evaluated to find out their therapeutic im-
portance [13]. For timely proper management of the
enteric fever the knowledge of the prevalence of the differ-
ent serovars of Salmonella and their antimicrobial suscep-
tibility patterns is of utmost importance [13].
In this study we studied the antimicrobial susceptibil-
ity patterns of Salmonella Typhi and Salmonella Paraty-
phi A isolated from the blood samples of the patients
suspected of suffering from enteric fever toward differ-
ent commonly used antibiotics. Reduced susceptibility of
nalidixic acid-resistant strains to fluoroquinolones was
also evaluated.
Methods
A cross-sectional study was carried out from November
2012 to May 2013, at a tertiary care hospital in Kathmandu,
Nepal. A total of 620 patients clinically suspected of suffer-
ing from enteric fever, were included in the study. Patients
who had already received antibiotics were not included in
the study. Blood samples were collected aseptically by vein
puncture and inoculated immediately into brain heart infu-
sion broth. The amount of blood collected from adults was
5 ml and that from children was 2 ml. The ratio of amount
of blood to that of brain heart infusion broth was main-
tained to be 1:10. After incubation, at 37 °C for 24, 48 and
72 hrs subcultures were done on MacConkey agar and
blood agar and were observed for bacterial growth after
24 hrs of aerobic incubation at 37 °C. Isolates were identi-
fied by biotyping (colony morphology, staining reaction
and biochemical characteristics) and serotyping using spe-
cific antisera (Denka Seiken Co. Ltd, Tokyo, Japan) [16].
Samples were considered negative for Salmonella, if no
growth was observed on subculture after 7 days of aerobic
incubation at 37 °C. Antimicrobial susceptibility testing for
Salmonella serovars was performed by Kirby Bauer disc
diffusion technique following CLSI guidelines [17]. The
antibiotic discs used were, ampicillin (30 μg), nalidixic acid
(30 μg), ofloxacin (5 μg), ciprofloxacin (5 μg), chloram-
phenicol (30 μg), ceftriaxone (30 μg), cotrimoxazole
(1.25 μg), cefotaxime (30 μg), azithromycin (15 μg), and
cefixime (30 μg). Minimum inhibitory concentrations
of nalidixic acid, ofloxacin and ciprofloxacin were de-
termined by agar dilution method as suggested by An-
drews [18] following CLSI guidelines [17]. Escherichia
coli ATCC 25922 was used for quality control. Statis-
tical analysis was performed by using SPSS 19.0.
Results
Out of 620 blood samples, 83 (13.38 %) samples were
culture positive for Salmonella spp. Out of total 83 Sal-
monella spp. isolated, 48 (57.83 %) were Salmonella
Typhi and 35 (42.26 %) were Salmonella Paratyphi A.
Antimicrobial susceptibility patterns of Salmonella spp.
toward different commonly used antibiotics
Among the antibiotics used for susceptibility testing of
the isolates, all the isolates were found to be susceptible
to cefixime, ceftriaxone, cefotaxime and azithromycin.
Similarly, 98.8 % of the Salmonella spp. were suscep-
tible to chloramphenicol and co-trimoxazole and about
97.6 % of the isolates were susceptible to ampicillin and
ofloxacin. Only 16.9 % of the isolates were found to be
susceptible to ciprofloxacin and nalidixic acid. 79.5 %
of the isolates were intermediate sensitive to ciprofloxa-
cin. Only one isolate was found to be multidrug resist-
ant (showing resistance to ampicillin, chloramphenicol,
cotrimoxazole and nalidixic acid) (Table 1).
Minimum inhibitory concentrations of nalidixic acid,
ciprofloxacin and ofloxacin for Salmonella isolates
About 24.1 % of the isolates had minimum inhibitory
concentration of nalidixic acid (≥ 16 μg/ml) and that of
ciprofloxacin (≥ 0.5 μg/ml) in resistant range. Similarly,
59 % of the isolates had minimum inhibitory concentra-
tion of nalidixic acid (≥ 16 μg/ml) in resistant range but
that of ciprofloxacin (0.064 μg/ml to 0.5 μg/ml) in inter-
mediate susceptible range. Again, 16.9 % of the isolates
had minimum inhibitory concentration of nalidixic acid
(≤ 16 μg/ml) and that of ciprofloxacin (≤ 0.064 μg/ml) in
susceptible range (Table 2). Likewise, 1.2 % of the iso-
lates had minimum inhibitory concentration of ofloxacin
Shrestha et al. Antimicrobial Resistance and Infection Control  (2016) 5:22 Page 2 of 5
(≥ 1 μg/ml) and that of nalidixic acid (≥ 16 μg/ml) in
resistant range. Approximately, 69.9 % of the isolates
had minimum inhibitory concentration of ofloxacin (≤
0.125 μg/ml) in susceptible range while that of nalidixic
acid (≥ 16 μg/ml) in resistant range. Around, 12 % of
the isolates had minimum inhibitory concentration of
ofloxacin (0.125 μg/ml to1 μg/ml) in intermediate sus-
ceptible range but that of nalidixic acid (≥ 16 μg/ml) in
resistant range. Finally, 16.9 % of the isolates had mini-
mum inhibitory concentration of nalidixic acid (≤
16 μg/ml) and that of ofloxacin (≤ 0.125 μg/ml) in sus-
ceptible range (Table 3).
Discussion
Similar rate of culture positivity as in our study (13.38 %)
was also found in another study conducted in Nepal
(15.6 %) [19]. Typhoid and paratyphoid, collectively
known as ‘enteric fever’, remains as one of the com-
monest causes of the fever in most parts of under de-
veloped world including Nepal [20]. The enteric fever is
endemic in most of the urban areas of Nepal including
Kathmandu, mainly due to cross contamination of the
drinking water with sewage [10, 21]. As in our study
higher prevalence of S. Typhi (57.83 %) in comparison
to S. Paratyphi A (42.26 %) (p < 0.05) was also reported
in another study conducted in Nepal {S. Typhi (64.1 %)
and S. Paratyphi A (35.9 %)} [22]. In both studies S.
Paratyphi B and C were not isolated.
In present study, the rate of nalidixic acid resistance,
which is a phenotypic marker for reduced susceptibility
to fluoroquinolones [23]; was observed high (83.1 %).
Similar rates of nalidixic acid resistance were also re-
ported in other studies conducted in India (86.27 %) [24]
and Nepal (91.1 % for S. Typhi and 90.0 % for S. Paraty-
phi A) [13]. In contrast to nalidixic acid resistance, in
present study re-emergence of susceptibility (98.8 % sus-
ceptibility to chloramphenicol and co-trimoxazole and
97.6 % susceptibility to ampicillin) to conventional first
line drugs used for treatment of enteric fever was ob-
served. Similar types of findings were also observed by
Garg et al. (1.96, 15.6, and 6.8 % resistance to chloram-
phenicol, ampicillin, and co-trimoxazole respectively)
[24], Acharya et al. (95.12 % susceptibility to all first line
antibiotics) [25], and Acharya et al. (more than 95.5 %
susceptibility to all first line antibiotics) [26]. The in-
creased use of the fluoroquinolones and the discontinu-
ation in the use of the conventional first line antibiotics
(ampicillin, chloramphenicol, and co-trimoxazole) for
treatment of the enteric fever for long periods of time
may be the reason behind the reduced susceptibility of
Salmonella strains to fluoroquinolones and re-emergence
of first line antibiotics susceptible S. Typhi and S. Paraty-
phi A isolates. Further, the loss of the plasmids responsible
for resistance to first line drugs may be the reason for the
re-emergence of the susceptible strains [13].
Among fluoroquinolones higher percentage of sus-
ceptibility was shown toward ofloxacin (97.6 %)
followed by ciprofloxacin (16.9 %). But we do not rec-
ommend to use ofloxacin for the treatment of enteric
fever in our setting, as high rate of nalidixic acid-
Table 1 Antimicrobial susceptibility patterns of Salmonella spp. toward different commonly used antibiotics
Antibiotics Number Resistance (%) Intermediate (%) Sensitive (%)
Ampicillin 83 2.4 0 97.6
Ceftriaxone 83 0 0 100
Cefotaxime 83 0 0 100
Cefixime 83 0 0 100
Nalidixic acid 83 83.1 0 16.9
Ciprofloxacin 83 3.6 79.5 16.9
Ofloxacin 83 0 2.4 97.6
Cotrimoxazole 83 1.2 0 98.8
Azithromycin 83 0 0 100
Chloramphenicol 83 1.2 0 98.8
Table 2 Susceptibility of the Salmonella spp. toward nalidixic
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resistance among Salmonella isolates was noted in our
study, which indicates the high probability of develop-
ing ofloxacin resistance in near future, if the drug is
used haphazardly. In Nepal, all the S. Typhi and S.
Paratyphi A isolates were reported as susceptible until
1998 but during 1999 to 2003 ciprofloxacin resistance
increased to 5 % in the S. Typhi and 13 % in S. Paraty-
phi A [9].
In contrast to our study, 100 % susceptibility of Sal-
monella Typhi and 96.7 % susceptibility of Salmonella
Paratyphi A to ciprofloxacin were observed in a study
by Chand et al. [13]. The increased haphazard use of
ciprofloxacin as empirical therapy for treatment of en-
teric fever in recent years may have contributed to this
discrepancy. Among cephalosporins and macrolides all
the isolates were susceptible to cefotaxime, cefixime, cef-
triaxone and azithromycin. But among the cephalospo-
rins, cefixime may attract more attention as drug of
choice as it can be used orally [27]. Only one isolate was
found to be multidrug resistant in present study and the
finding correlated with the previous study that reported
the decreasing trend in multidrug resistant isolates dur-
ing the period of 2000–2004 [28]. Due to irrational use
of antibiotics, the rate of drug resistance among bacteria
is increasing and the situation is worse in developing
countries [29, 30]. So antibiotics should be used only on
the basis of culture and sensitivity report.
Our findings will be helpful for the clinician to choose
the appropriate empirical therapy for the treatment of
enteric fever. Further it will also be helpful to make pol-
icy for empirical therapy for treatment of enteric fever.
Limitations of the study
Due to short duration of the time available for research
and lack of resources we could not include more sam-
ples in the study. Further, due to lack of sophisticated la-
boratory and lack of fund we could not confirm our
results with molecular techniques. Minimum inhibitory
concentrations of all the antibiotics used in antimicrobial
susceptibility testing could not be determined. This is a
study conducted in only one hospital, so multi-centered
study covering wide geographical area would have gener-
ated more significant result.
Conclusions
The present study revealed the increased rate of nali-
dixic acid resistant Salmonella spp. associated with re-
duced susceptibility to fluoroquinolones in contrast to
increased susceptibility of the strains to conventional
first-line drugs ampicillin, chloramphenicol, and cotri-
moxazole in Kathmandu, Nepal. So, the conventional
first-line drugs along with the third generation cephalo-
sporins and azithromycin can be used as empiric therapy
for treatment of enteric fever in our setting. Multi-
centered studies covering wide geographical area and
large population are required to generate more signifi-
cant data regarding the susceptibility of the Salmonella
spp. toward ampicillin, co-trimoxazole and chloram-
phenicol and to determine the possibility of using these
drugs for empirical therapy for treatment of enteric
fever.
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